COVID 19 Supplement - NIH TCF TASK AREA B-1

美国国立卫生研究院四聚体核心设施(TCF)分发高质量的试剂，用于检测固有T细胞和经典的CD4和CD8T细胞群。该设施还进行研发，以生产新的试剂和改进现有的四聚体技术。TCF正在生产MHC I类和II类四聚体，用于分离和鉴定SARS-CoV2特异性的CD4和CD8 T细胞，并正在开发用于检测和表征SARS-CoV2特异性B细胞的SARS-CoV-2刺突蛋白四聚体。到目前为止，已向社区分发了56个MHC四聚体，另有35个正在进行中。随着COVID相关研究的增加，订单预计将增加。随着新的T细胞表位和B细胞抗原靶标的确定，将生产和分发更多的试剂。这些四聚体试剂将是评估新冠肺炎患者的获得性免疫反应或对候选疫苗的反应的宝贵工具。

The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations. This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies. The TCF is producing MHC class I and class II tetramers for isolation and characterization of SARS-CoV2-specific CD4 and CD8 T cells, and is also developing SARS-CoV-2 Spike protein tetramers for detection and characterization of SARS-CoV2 specific B cells. Thus far, 56 MHC tetramers have been distributed to the community, an additional 35 are in-process. Orders are expected to increase as COVID-related research increases. Additional reagents will be produced and distributed as new T cell epitopes and B cell antigen targets are identified. These tetramer reagents will be invaluable tools for evaluation of adaptive immune responses in COVID-19 patients or in response to candidate vaccines.